

## Quantitative methylation detection in DNA samples

### Field of the Invention

5

This invention relates to the analysis of nucleic acids, especially to the analysis of methylation patterns in genomic DNA by providing a means of detecting nucleotides, that are characteristic for methylated sites after bisulfite treatment of the genomic DNA. The method  
10 utilises the incorporation of labels and the detection of fluorescence resonance energy transfer (FRET) of the amplified sample DNA.

15

### Prior art

#### DNA Methylation

20

The levels of observation that have been studied in recent years in molecular biology have concentrated on genes, the translation of those genes into RNA, and the transcription of the RNA into protein. There has been a more limited analysis of the regulatory mechanisms associated with gene control. Gene regulation, for example, at what stage of development of the individual a  
25 gene is activated or inhibited, and the tissue specific nature of this regulation is less understood. However, it can be correlated with a high degree of probability to the extent and nature of methylation of the gene or genome. From this observation it is reasonable to infer  
30 that pathogenic genetic disorders may be detected from irregular genetic methylation patterns.

35

The efforts of the Human Genome project are concentrated on the sequencing of the human genome. It is expected that this will yield considerable therapeutic and diagnostic benefits for the treatment of disease.

However, these efforts have so far been unable to address a significant aspect of genetic disorders, the epigenetic factor. The epigenetic regulation of gene transcription has been shown to effect many disorders. One of the most significant epigenetic mechanisms so far identified has been the methylation of cytosine. The methylation of cytosine at the 5 position is the only known modification of genomic DNA. Although the exact mechanisms by which DNA methylation effects DNA transcription are unknown, the relationship between disease and methylation has been well documented. In particular methylation patterns of CpG islands within regulatory regions of genome appear to be highly tissue specific. Therefore, it follows that misregulation of genes may be predicted by comparing their methylation pattern with phenotypically 'normal' expression patterns. The following are cases of disease associated with modified methylation patterns.

- Head and neck cancer (Sanchez-Cespedes M et al. „Gene promoter hypermethylation in tumors and serum of head and neck cancer patients“ Cancer Res. 2000 Feb. 15;60 (4):892-5)
- Hodgkin's disease (Garcia JF et al „Loss of p16 protein expression associated wiht methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease“ Lab invest 1999 Dec; 79 (12):1453-9)
- Gastric cancer (Yanagisawa Y et al. „ Methylation of the hMLH1 promoter in familial gastric cancer with microsatellite instability“ Int J Cancer 2000 Jan 1; 85 (1):50-3)
- Prader-Willi/Angelman's syndrome (Zeschnigh et al „Imprinted segments in the human genome: different DNA methylation patterns in the Prader Willi/Angelman syndrome region as determined by the genomic sequencing method“ Human Mol. Genetics (1997) (6) 3 pp 387-395)

- ICF syndrome (Tuck-Muller et al „CMDNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients" Cytogenet Cell Genet 2000; 89(1-2):121-8
- 5 - Dermatofibroma (Chen TC et al „Dermatofibroma is a clonal proliferative disease" J Cutan Pathol 2000 Jan;27 (1):36-9)
- Hypertension ( Lee SD et al. „ Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension" J clin Invest 1998  
10 Mar 1, 101 (5):927-34)
- Autism (Klauck SM et al. „Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients" Human Genet 1997 Aug; 100 (2) : 224-9)
- 15 - Fragile X Syndrome ( Hornstra IK et al. „ High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome" Hum Mol Genet 1993 Oct, 2(10):1659-65)
- Huntigton's disease (Ferluga J et al. „possible organ and age related epigenetic factors in Huntington's  
20 disease and colorectal carcinoma" Med hyptheses 1989 May;29(1);51-4

25 All of the above documents are hereby incorporated by reference.

#### Bisulphite treatment

A relatively new and currently the most frequently used method for analyzing DNA for 5-methylcytosine is based  
30 upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behaviour. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the  
35 original DNA is converted in such a manner that methylcytosine, which originally could not be

distinguished from cytosine by its hybridisation behaviour, can now be detected as the only remaining cytosine using "normal" molecular biological techniques, for example, by amplification and hybridisation or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analysed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996 Dec 15;24(24):5064-6). Using this method, it is possible to analyse individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analysed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyse very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.

An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Rein, T., DePamphilis, M. L., Zorbas, H., Nucleic Acids Res. 1998, 26, 2255.

To date, barring few exceptions (e.g., Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet. 1997 Mar-Apr;5(2):94-8) the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and either

- completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation imprint. Nat Genet. 1997 Nov; 17(3):275-6) or individual cytosine positions are detected by a primer extension reaction
- 5 (Gonzalzo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 1997 Jun 15;25(12):2529-31, WO Patent 9500669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a
- 10 sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997 Jun 15;25(12):2532-4). In addition, detection by hybridisation has also been described (Olek et al., WO 99 28498).
- 15 Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic DNA. Bioessays. 1994 Jun;16(6):431-6, 431; Zeschnigk M, Schmitz B, Dittrich B,
- 20 Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Hum Mol Genet. 1997 Mar;6(3):387-95; Feil R, Charlton J, Bird AP,
- 25 Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. Nucleic Acids Res. 1994 Feb 25;22(4):695-6; Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R. Genomic sequencing indicates a correlation between DNA
- 30 hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines. Gene. 1995 May 19;157(1-2):261-4; WO 97 46705, WO 95 15373 and WO 45560.
- 35 Fluorescence Resonance Energy Transfer(FRET)

Fluorescence resonance energy transfer (FRET) is an interaction between two molecules wherein the excited state of one molecule (the donor) transfers energy to the other molecule (the acceptor). The donor molecule is a fluorophore while the acceptor molecule may or may not be. The energy transfer occurs without the emission of photons, and is based on dipole-dipole interactions between the two molecules. Molecules that are commonly used in FRET include fluorescein, N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4'-dimethylaminophenylazo) benzoic acid (DABCYL), and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS). Basic conditions for FRET include the following:

- Close proximity between the donor and acceptor molecules (typically 10-100 Å).
- The emission spectrum of the donor molecule must overlap the absorption spectrum of the acceptor molecule. The transition dipole orientations of the donor and acceptor molecules must be approximately parallel.
- The extent of the energy transfer is dependent on the distance between the two molecules, and the overlap between the donor and acceptor spectra. It can be described by the following equation:

$$k_t(r) = t_{D-1} \cdot (R_0/r)^6$$

wherein  $r$  is the distance between the donor and the acceptor

$t_D$  is the lifetime of the donor in the absence of energy transfer

$R_0$  is termed the Förster distance.

The efficiency of the energy transfer (for a single donor-acceptor pair) is given by:

$$E = R_0^6 / (R_0^6 + r^6)$$

Förster distances are typically in the range of 30-60 Å. Therefore FRET can be used as a highly sensitive method of measuring microscopic distances, this is particularly useful within the field of molecular biology where it has been utilised in a number of ways. It has been used in the study of protein structure, assembly, distribution, conformation and interactions, as well as the study of cell membranes and immunoassays. FRET has also been used in a number of ways in the analysis of nucleic acids. This includes the analysis of the structure and conformation of nucleic acids, hybridisation, PCR, sequencing and primer extension assays.

Another class of probe labels include fluorescence quenchers. The emission spectra of a quencher overlaps with a, fluorescent dye such that the fluorescence of the fluorescent dye is substantially diminished, or quenched, by the phenomena of fluorescence resonance energy transfer „FRET“ (Clegg (1992) Meth. Enzymol., 211:353-388). A fluorescent reporter dye and quencher joined in a configuration that permits energy transfer from the fluorophore to the quencher may result in a reduction of the fluorescence of the fluorescent dye. The reporter is a luminescent compound that can be excited either by chemical reaction, producing chemiluminescence, or by light adsorption, producing fluorescence. The quencher can interact with the reporter to alter its light emission, usually resulting in the decreased emission efficiency of the reporter. The efficiency of this quenching phenomenon is directly correlated with the distance between the reporter molecule and the quencher molecule (Yaron (1979) Analytical Biochemistry, 95:228-35).

Particular quenchers include but are not limited to rhodamine dyes such as tetramethyl-6-carboxyrhodamine

(TAMRA) or tetrapropano-6-carboxyrhodamine (ROX) (Bergot, U.S. Patent No. 5,366,860).

#### Enzymatic Amplification

5 PCR is a commonly used technique that has been described, for example in US patents numbers 4,683,195, 4,683,202, and 4,800,159. Briefly, it is the amplification of a nucleic acid sequence by repetitive cycles of annealing and extending primer to single stranded nucleic acids  
10 followed by the denaturation of the resultant double stranded molecule. PCR, (and variations thereof) has a multitude of applications and is one of the key technologies involved in most forms of nucleic acid analysis and manipulation.

15 An important variation is the Multiplex-PCR, where more than 2 specific primer are used and a multitude of different specific amplifications are obtained in one reaction chamber.

20 There are several commonly used methods for the detection of PCR products, such as gel electrophoresis and the use of labelled primer oligonucleotides and nucleoside triphosphates. The use of fluorescent labelled  
25 nucleotides and oligomers within PCR for nucleic acid analysis is also known.

#### PNA FRET probes

30 PNA can hybridise to its target complement in either a parallel or anti-parallel orientation. However, the anti-parallel duplex (where the carboxyl terminus of PNA is aligned with the 5' terminus of DNA, and the amino terminus is aligned with the 3'-terminus of DNA) is typically more stable (Egholm (1993) Nature, 365:566-68).  
35 PNA probes are known to bind to target DNA sequences with high specificity and affinity (Coull, US Patent No.



6,110,676). The PNA FRET probe examples of the present invention, with reporter or quencher moieties, are designed such that the PNA anneals in the anti-parallel orientation with the target sequences.

5

PNA may be synthesized at any scale on automated synthesizers. The PNA FRET probes may be synthesized on many of the commonly used solid supports. After synthesis is complete, the PNA may be cleaved from the support,  
10 purified, analysed and quantitated. Fluorescent-labeled PNA probes have demonstrated desirable properties in hybridization assays (Hyldig-Nielsen, U.S. Patent No. 5,985,563).

15 Genomic DNA for further amplification is obtained from DNA of cells, tissue or other test samples using standard methods. This standard methodology is found in references such as Fritsch and Maniatis eds., Molecular Cloning: A Laboratory Manual, 1989.

20

#### Real Time PCR

Real time PCR monitoring using fluorescence has been described in several manners. Firstly, the binding of double stranded DNA specific fluorescent dyes such as  
25 ethidium bromide allows for the monitoring of the accumulation of PCR product by correlation with increased fluorescence. A second detection method, polymerase mediated exonuclease cleavage utilises the 5' exonuclease activity of polymerases such as Taq. An oligonucleotide  
30 probe that is complementary to the PCR product, yet distinct from the PCR primer is labelled with a FRET pair such that the donor molecule is quenched by an acceptor molecule. During PCR amplification, the 5' exonuclease proceeds to digest the probe, separating the FRET pair  
35 and leading to increased fluorescence. A variation on this technology uses a nucleic acid wherein the FRET pair

is internally quenched, for example, by having a hairpin conformation. Upon hybridisation to a sequence of interest, the FRET pair is separated and the donor molecule emits fluorescence. This technology can be used, for example for the analysis of SNPs.

An alternative technology is based on the use of two species of hybridisation probes, each labelled with a member of a FRET pair. Upon hybridisation of both probes to the target sequence in adequate proximity, a fluorescent signal is emitted. Again, this technology may be used for the detection of SNPs.

A major advantage of the use of such FRET based PCR technologies is that the reaction may be monitored in a closed tube reaction, suitable for use in high and medium throughput and reducing the probability of contamination.

#### Description of the Invention

According to the present invention there is provided a method for the cytosine methylation detection in a DNA sample, comprising the following steps:

- a) a genomic DNA sample is treated in a manner capable of distinguishing methylated from unmethylated cytosine bases;
- b) the pre-treated DNA is amplified using at least one oligonucleotide primer, a polymerase and a set of nucleotides of which at least one is marked with a first type of label;
- c) a sequence-specific oligonucleotide or oligomer probe is hybridized to the amplification product and a FRET occurs if the oligonucleotide or oligomer probe, marked with a second type of label, binds in close proximity to one of the labeled nucleotides that was incorporated into the amplification product;

d) the level of methylation of the sample is determined by the level of interaction between said first and second type of label.

5 According to the invention it is preferred that the first type of label is a donor fluorophore and the second type of label is an acceptor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured. It is further preferred that the first type of  
10 label is an acceptor fluorophore and the second type of label is a donor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured.

15 A further preferred embodiment of the present invention is characterised in that the nucleotides of step b) contain a fluorescent moiety and the probe in step c) a quencher moiety. It is also preferred according to the invention that the nucleotides of step b) contain a  
20 quencher moiety and the probe in step c) a fluorescent moiety.

According to the invention it is also preferred that the polymerase has no 5' to 3' exonuclease activity in order  
25 to prevent degradation of the probe.

It is further preferred according to the invention that a change in fluorescence intensity is monitored in real-time during the amplification reaction.

30 It is also especially preferred according to the present invention that a change in fluorescence intensity is monitored at end-point of target amplification.

According to another preferred embodiment of the present invention the amplification reaction is achieved with the polymerase chain reaction (PCR).

5 According to the invention it is preferred that the probe contains only one CpG or that the probe contains several CpGs. Especially in this case it is further preferred that each probe for each CpG has a fluorescent label.

10 In a further preferred embodiment of the present invention the probe can be end labeled or internally labeled.

15 It is also preferred according to the invention that the methylation information is determined by the change in fluorescence intensity during subsequent rounds or cycles of PCR.

20 It is also preferred that the sample DNA is only amplified by chosen PCR primers if a certain methylation state is present at a specific site in the sample DNA.

25 According to the present invention a method is preferred wherein the sample DNA is only amplified if a certain methylation state was present at a specific site in the sample DNA, the sequence context of which is essentially complementary to one or more oligonucleotides or PNA oligomers which are additionally used in the PCR reaction.

30 It is also preferred that the amplification from the 3'-end of the probe is blocked by phosphorylation.

35 According to the invention it is also preferred that a melting curve is generated at the end of the PCR to gather additional data.

It is especially preferred within the scope of the present invention that the fluorescent moiety is a fluorescein dye, a rhodamine dye, or a cyanine dye. Especially preferred is also that the quencher moiety is a rhodamine dye.

It is an especially preferred feature of the present invention that the deamination treatment of the DNA is performed with a bisulfite reagent.

It is also preferred according to the invention that the DNA sample is cleaved prior to deamination treatment with restriction endonucleases.

In a preferred embodiment of the method of the invention the DNA sample is isolated from mammalian sources e.g. cell lines, blood, sputum, faeces, urine, cerebrospinal fluid, tissue embedded in paraffin, for example, ocular tissue, intestine, kidney, brain, heart, prostate, lung, chest or liver, histological slides and all possible combinations.

It is another preferred embodiment of the present invention to use of a pre-treated genomic DNA within the method according to the present invention for the determination of the methylation status of a corresponding genomic DNA.

Another object of the present invention is to provide a diagnostic kit for the detection of the methylation of cytosine bases in genomic DNA samples, comprising reagents for the selective deamination of cytosine bases in genomic DNA, one or more primers and labeled nucleotides for the amplification step, a detectable

probe and optionally protocols or instructions for one of the methods according to one of the preceding claims.

5 The invention describes a method to determine the presence of specific CpG dinucleotides in a fragment of DNA using fluorescence resonance energy transfer (FRET). This can be used to obtain information about sequence properties of a sample DNA fragment. For example, a point mutation could be identified in a fragment if a  
10 nucleotide is present in its sequence as a result of this mutation which is not present in the wild type.

15 The method is preferably used to measure cytosine methylation. As mentioned above, bisulphite leads to the selective deamination of cytosine, leaving 5-methylcytosine essentially unchanged. Methylation of cytosine occurs almost exclusively in the sequence context 5'-CG-3'. Therefore, after bisulphite treatment, certain dinucleotides containing C do not occur anymore  
20 in one strand, but they may still occur in the complementary strand formed in the amplification of bisulphite treated DNA, for example using the polymerase chain reaction (PCR).

25 This invention provides a method for visualizing the methylation status of a CpG at defined positions in a very sensitive way with very low background signal.

30 The method briefly comprises the following steps of

- a) treating a genomic DNA sample in a manner capable of distinguishing methylated from unmethylated cytosine bases;
- 35 b) amplifying the pre-treated DNA using at least one oligonucleotide primer, a polymerase and a set of

nucleotides of which at least one is marked with a first type of label;

5 c) hybridising a sequence-specific oligonucleotide or oligomer probe to the amplification product, a FRET occurs if the oligonucleotide or oligomer probe, marked with a second type of label, binds in close proximity to one of the labeled nucleotides that was incorporated into the amplification product;

10

d) determining the level of methylation of the sample by measuring by the level of interaction between said first and second type of label.

15

In a preferred embodiment of the invention, the first type of label is a donor fluorophore and the second type of label is an acceptor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured.

20

In a further preferred embodiment of the invention, said first type of label is an acceptor fluorophore and the second type of label is a donor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured.

25

It is preferred that two or more CpGs are separately interrogated in an amplification reaction.

30

Preferably, separate probes for each CpG are used, each with its own fluorescent label.

35

The instant invention also enables a multiplex PCR to rapidly determine optimal assay parameters and a fast, cost-effective, and accurate system for the quantitative analysis of target analytes. A multiplexed assay can for

example be designed in a standard 96 well microtiter plate format at room temperature using conventional robotic systems for sample delivery and preparation.

- 5 Preferably, the oligonucleotide or oligomer probes used comprise one or more nucleotide analogs selected from a nucleobase analog, a 2'-deoxyribose analog, an internucleotide analog, PNA or LNA.
- 10 Although the detection of C or G nucleotides (in the complementary strand) after bisulphite treatment in the context CpG is the preferred application, also any other nucleotide or polymorphism can in principle be detected. The preferred application is to determine the methylation status of certain CpG positions by determining the level of interaction between an unconverted C in the bisulphite treated DNA and a labeled oligonucleotide hybridised thereto. Accordingly, Guanin in the complementary strand (after PCR) can be used for the same purpose.
- 15
- 20 Also, converted positions after bisulphite treatment can be identified by detecting thymine (or adenine in the complementary strand) at selected positions using this technology. However, design of probes becomes more difficult as it is not possible to distinguish between T that was in the original genomic sequence and T positions that were created through bisulphite conversion, indicating lack of methylation at the respective cytosines.
- 25
- 30 In more detail, this method for the detection of specific nucleotides in a DNA sample is characterized in that an isolated genomic DNA sample is treated in a manner capable of distinguishing methylated from unmethylated cytosine bases and the pre-treated DNA is amplified using at least one oligonucleotide primer, a polymerase and a
- 35



set of nucleotides at least one of which is marked with a first type of label, in a first embodiment a donor fluorophore and in a second embodiment an acceptor fluorophore.

5

Preferably, the acceptor and donor dyes (fluorophores) are chosen in a way that the emission wavelength of the donor dye overlaps with the excitation wavelength of the acceptor dye. It is preferred that the emission and excitation spectra are sharp peaks and that the emission spectra of the dyes are unlikely to overlap.

10

It is preferred that the polymerase has no 5' to 3' exonuclease activity to prevent degradation of the probe.

15

For example, dGTP is labeled with a fluorescent dye. The labeled dGTP is incorporated only where there was a methylated cytosine in the original DNA sample. Alternatively, the dCTP can be labeled with a fluorescent dye.

20

After the extension phase, the DNA is denaturated and then allowed to reanneal.

25

A sequence-specific oligonucleotide or oligomer probe (referred to as oligomer probes if DNA analogs like PNA are used), marked with a second type of label that is in a first embodiment an acceptor fluorophore and in a second embodiment a donor fluorophore hybridizes to the amplification product. Preferably, amplification from the 3' end of the probe is blocked by phosphorylation (with dideoxynucleotides).

30

The labels are preferably introduced into the oligonucleotide probes by standard enzymatic methods, such as the use of 5' labeled amplification primers for

35

5' labeling or fluorescent-labeled base analogs for internal labeling.

A FRET reaction occurs if the fluorescently labeled oligonucleotide, preferably in one embodiment a fluorescent moiety binds in close proximity to a nucleotide labeled with a quencher moiety, that was incorporated into the amplification product or in another embodiment a quencher moiety that binds in close proximity to a nucleotide labeled with a fluorescent moiety that was incorporated into the amplification product (Fig.1).

It is preferred that the probe is positioned in several places relative to the CpG. The conformation of the DNA controls the spacing of the two fluorescent dyes. Preferently, the positioning is optimized for each CpG.

In a preferred embodiment, the probe is separated from the amplification primers or alternatively it is attached to the 5' end of one of the primers.

This way, the level of methylation can be determined, identifying the CG dinucleotides. If a TG dinucleotide is present instead, no FRET will be observed. Therefore, this method can be directly used to monitor DNA methylation (Fig. 2).

In a preferred embodiment of the invention a real time monitoring of the FRET signal is performed during the amplification reaction. This way, the progress of the amplification can be examined (Fig.3). Very preferably the amplification reaction is a polymerase chain reaction (PCR), even though other amplification procedures for example cloning or SDA (Strand Displacement Amplification) are also preferred.

In another preferred embodiment of the invention the change in fluorescence intensity is monitored at end-point of target amplification. End-point analysis of the PCR entails fluorescent dye signal measurement when thermal cycling and amplification is complete. Results are reported in terms of the change in fluorescence, i.e. fluorescence intensity units, of the fluorescent dye signal from start to finish of the PCR thermal cycling, preferably minus any internal control signals.

It is also preferred that a melting curve is generated at the end of the PCR to gather additional data.

In another preferred embodiment of the invention the CpG dinucleotide occurs only once in the amplification product. As outlined above, this is very helpful if the presence of the FRET signal is directly used to draw conclusions about the sequence characteristics of the sample DNA.

For example, if only one labeled CG is present in an amplification product of a bisulphite treated sample and a fluorescently labeled probe binds in close proximity to it, a FRET occurs and direct conclusions can be drawn that a methylated cytosine was present in a certain position in the genomic DNA sample.

If several labeled CGs are present for example in an amplification product of a bisulphite treated sample and probes bind in close proximity to them, each with its own fluorescent label, several FRET reactions occur and conclusions can be drawn about the methylated cytosines from all sites involved.

In a further preferred embodiment of the invention the methylation information is determined by the change in fluorescence intensity during subsequent rounds of PCR.

- 5 Preferably, the sample is illuminated during the amplification reaction with light of appropriate wavelength.

10 In a preferred embodiment of the invention, prior to the PCR either essentially all cytosines in the DNA sample are selectively deaminated, but 5-methylcytosines remain essentially unchanged or essentially all 5-methylcytosines in the DNA sample are selectively deaminated, but cytosines remain essentially unchanged.

15 Cytosine-guanine (CpG) dinucleotides are detected, allowing conclusions about the methylation state of cytosines in said CpG dinucleotides in said DNA sample. This deamination is preferably performed using a bisulphite reagent.

20 Preferably, the sample DNA is only amplified by chosen PCR primers if a certain methylation state is present at a specific site in the sample DNA the sequence context of which is essentially complementary to one or more of said

25 chosen PCR primers. This can be done using primers annealing selectively to bisulphite treated DNA which contains in a certain position either a TG or a CG, depending on the methylation status in the genomic DNA. Primers can be designed for both cases. A primer could

30 contain a G at its 3'-end, therefore it would only bind to a DNA containing a C at the respective position and therefore this primer will only or preferentially amplify methylated DNA because the C is indicative of a methylation in this position after bisulphite treatment.

35 This method is known as MSP, methylation sensitive PCR.

In another preferred embodiment of the invention, the sample DNA is only amplified if a certain methylation state is present at a specific site in the sample DNA the sequence context of which is essentially complementary to one or more oligonucleotides or PNA oligomers which are additionally used in the PCR reaction. These oligonucleotides or PNA oligomers bind selectively to the template DNA and prevent its amplification depending on the methylation state of the DNA prior to bisulphite conversion.

Preferably, the fluorescent moiety is a fluorescein dye, a rhodamine dye, or a cyanine dye and the quencher moiety a rhodamine dye.

In another preferred variant of the invention the DNA sample is cleaved prior to deamination (for example bisulphite) treatment with restriction endonucleases.

Preferred is also a method whereby the enzymatic amplification of the treated DNA is such that only one strand of the DNA sample is amplified.

Preferably, the DNA sample is isolated from mammalian sources e.g. cell lines, blood, sputum, faeces, urine, cerebrospinal fluid, tissue embedded in paraffin, for example, ocular tissue, intestine, kidney, brain, heart, prostate, lung, chest or liver, histological slides and all possible combinations.

Another embodiment of the present invention is a diagnostic kit for the detection of the methylation of cytosine bases in genomic DNA samples, comprising reagents for the selective deamination of cytosine bases in genomic DNA, one or more primers and fluorescently labeled nucleotides for the amplification step and

optionally protocols or instructions for one of the methods according to one of the preceding claims.

5 This kit can also comprise several additional items for example detectable probes.

10 The components of said kit, as an example, could comprise receptacles for the following in sufficient quantities to carry out the method:

- 1) Reagents for the bisulfite conversion of sample DNA.
- 2) Reagents for the amplification of the converted sample and incorporation of fluorophore labelled nucleotides including:
  - 15 a) nucleic acid primer and
  - b) appropriate mix of nonlabeled and fluorophore labeled nucleotides and
  - c) DNA polymerase able to incorporate the fluorophore labelled nucleotides
- 20 3) Instructions for use

25 The term 'instructions for use' should cover a tangible expression describing the reagent concentrations for the assay method, parameters such as the relative amounts of reagents to be combined, maintenance times for reagents/sample mixtures, temperature, buffer conditions and the like.

30 In the following, steps of preferred embodiments of the invention are described in more detail.

#### DNA Isolation

35 The genomic DNA sample must be isolated from tissue or cellular sources. For mammals, more preferably humans, the DNA sample may be taken from any tissue suspected of expressing the target site within the genome and also

from, such as cell lines, blood, sputum, faeces, urine, cerebrospinal fluid, tissue embedded in paraffin; for example, tissue of intestine, kidney, brain, heart, prostate, lung, chest or liver, histological slides, but not limited to those. Extraction may be by means that are standard to one skilled in the art, these include the use of detergent lysates, sonification and vortexing with glass beads. Once the nucleic acids have been extracted the genomic double stranded DNA is used for analysis.

10

#### Bisulfite Treatment

The sample DNA is then treated chemically in order to convert the unmethylated cytosine bases into uracil. The chemical modification may be by means of, for example, (but not limited to) a bisulfite solution. Said chemical conversion may take place in any format standard in the the art. This includes but is not limited to modification within agarose gel or in denaturing solvents.

20 Wherein the chemical modification takes the form of a bisulfite treatment of the DNA the following steps may be followed.

The double stranded DNA must be denatured. This may take the form of a heat denaturation carried out at variable temperatures. For high molecular weight DNA, the denaturation temperature is generally greater than 90 °C. However, the analysis may be upon smaller fragments which do not require such high temperatures. In addition as the reaction proceeds and the cytosine residues are converted to uracil the complementarity between the strands decreases. Therefore, a cyclic reaction protocol may consist of variable denaturation temperatures.

35 The bisulfite conversion then consists of two important steps, the sulfonation of the cytosine and the subsequent

deamination. The equilibra of the reaction are on the correct side at two different temperatures for each stage of the reaction. Taking into account the kinetics of the reactions it is preferable that the reaction takes place under cyclic conditions, with changing temperatures. The temperatures and length at which each stage is carried out may be varied according to the specific requirement of the situation. However, a preferred variant of the method comprises a change of temperature from 4 C (10 minutes) to 50 C (20 minutes). This form of bisulfite treatment is state of the art with reference to WO 99/28498.

Said chemical conversion may take place in any format standard in the art. This includes but is not limited to modification within agarose gel, in denaturing solvents or within capillaries.

Bisulfite conversion within agarose gel is state of the art and has been described by Olek et al, Nucl. Acids. Res. 1996, 24, 5064-5066. The DNA fragment is embedded in agarose gel and the conversion of cytosine to uracil takes place with hydrogensulfite and a radical scavenger. The DNA may then be amplified without need for further purification steps.

In a further preferred embodiment the DNA conversion may take place without an agarose matrix. The DNA may incubated at increased temperatures with hydrogensulfite and a radical scavenger. Said reaction takes place within an organic denaturing solvent. Examples of denaturing solvents include, but are not limited to, Polyethylene glycol dialkyl polyethylenglycol-dialkylether, dioxane and substituted derivatives, urea or derivatives, acetonitrile, primary alcohols, secondary alcohols, tertiary alcohols, DMSO or THF.



In a further embodiment, prior to chemical treatment the DNA sample is transferred into a heatable capillary that is permeable to small molecules. The reaction steps of the chemical modification may then be carried out in the capillary tubes by means of the addition and removal of reagents through connected capillaries.

Subsequent to the chemical treatment the two strands of the DNA may no longer be complementary.

Amplification and Incorporation of labeled Nucleotides  
Fractions of the so treated genomic DNA are then enzymatically amplified using oligonucleotide primers. The length and design of said primers may be specific to the area of the genome to be analysed. As such a wide range of primers are suitable for use in this technique. Such primer design is within the state of the art.

An appropriate fraction of the nucleotides presented in the amplification reaction, for example the G nucleotides, are labeled with either a first or second type of label, the first type being a fluorophore and the second type a quencher or vice versa. Acceptable fluorophores for labeling the nucleotides are well known to those skilled in the art and include, but are not limited to, fluorescein, rhodamine, cyanine, phycoerythrin, Cy 5, Cy 5.5, Cy 7, LC Red 640 or LC Red 705 whereas the acceptable quenchers are rhodamine dyes. Attaching those dyes to the nucleotides lies within the state of the art.

In a preferred embodiment of this invention the sample is illuminated during the amplification reaction with light of appropriate wavelength.

The skill of the invention lies in the interpretation of a FRET signal during states, where a sequence-specific oligonucleotide probe is hybridized to an amplification product and a FRET occurs if the fluorescently labeled oligonucleotide binds in close proximity to one of the labeled nucleotides that were incorporated into the amplification product in order to gain knowledge of the methylation state of the sample.

#### Advanced Data Processing

It is anticipated that the method will be used for the high throughput analysis of genomic DNA samples. Therefore, the invention also involves analysis of data using a computing device. In a preferred embodiment said device may comprise one or more databases. In a further preferred embodiment said device may comprise one or more learning algorithms.

#### Description of the Drawings

##### Figure 1

##### Legend:

- 1: Bisulfite Treatment
- 2: Incorporation of labeled nucleotide
- 3: Detection of target by Fret
- 4: Real-Time PCR

DNA extracted from a tissue is treated with sodium bisulfite (A). Into the bisulfite treated DNA (single strand (B) dGTPs are incorporated (C+D) that are labeled with a fluorescent dye during a real-time PCR. A FRET occurs if the fluorescently labeled oligonucleotide binds in close proximity to one of the labeled nucleotides that was incorporated into the amplification product (E).

Figure 2

## Legend:

1. Bisulfite treatment
- 5 2. PCR with labeled dGTP
3. Extension of primer
4. Denaturation
5. Annealing and fluorescence monitoring
6. More Cycles

10

15

20

DNA of interest is chemically treated, the only cytosines remaining in the sequence are those that were methylated in the original sample. PCR primers designed to target one of the DNA strands anneal to the template and extend it by incorporating labeled nucleotides (dGTP). The labeled dGTP is incorporated only where there was a methylated cytosine in the original DNA sample. After the extension phase, the DNA is denaturated, allowed to reanneal and the fluorescence monitored. With each round of PCR, more targets complementary to the probe accumulate. The amount of fluorescence emitted from the probe is measured.

Figure 3

25

## Legend:

1. PCR with unlabeled dCTP, dATP, dTTP and labeled dGTP
2. Hybridization of fluorescent-labeled gene specific oligo-nucleotide
- 30 3. FRET, real-time fluorescence detection

35

A PCR is performed with primers that target one of the DNA strands. The first primer anneals to the template and extends it by incorporating the appropriate nucleotides. One of the nucleotides, in this case dGTP, is labeled with a fluorescent dye. A sequence-specific

oligonucleotide probe hybridizes to the site of interest.  
If the labeled guanine is present, a FRET reaction  
occurs. The energy emitted from the guanine is  
transferred to the label on the probe. The energy emitted  
5 from the probe is detected by real-time fluorescence  
detection.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221